Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PE Biosystems DNA Analyzer Demand, Strong Sales Boost Stock 26% In Q3

This article was originally published in The Gray Sheet

Executive Summary

Continued strong demand for the ABI Prism 3700 DNA analyzer, order growth across a broad range of additional products and release of financial results ahead of some analysts' estimates contributed to a 25.9% jump in PE Biosystems' stock price during the third quarter.

You may also be interested in...



Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales

A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.

GE Medical Systems To Control U.S. C-Arm Imaging Market Via OEC Purchase

GE Medical Systems will gain a controlling stake of the U.S. mobile C-arm fluoroscopy imaging market through its $480 mil. purchase of OEC Medical Systems, announced Aug. 9.

Boston Scientific Pursues Dual Strategy In Addressing RotaLink Recall

Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.

Related Content

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel